BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares dropped 4.4% to $7.16 following report of Form 4 filing from Baker Bros. Baker Bros bought 106,800 shares of BioCryst Pharmaceuticals at $7.28 per share. Share volume totaled 236,000, compared to an all-day average of 859,000
